A carregar...

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first‐in‐human trial in healthy postmenopausal women

AIMS: Preterm birth remains a significant risk for later disability. The selective inhibition of the prostaglandin F(2α) receptor has significant advantages for a tocolytic. The prodrug OBE022 and its metabolite OBE002 are novel prostaglandin F(2α) receptor antagonists under development for treating...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Pohl, Oliver, Marchand, Line, Gotteland, Jean‐Pierre, Coates, Simon, Täubel, Jörg, Lorch, Ulrike
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6046484/
https://ncbi.nlm.nih.gov/pubmed/29708281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!